KYTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Kyverna Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.82 |
| 52 Week High | US$35.06 |
| 52 Week Low | US$6.46 |
| Beta | 0 |
| 11 Month Change | -17.13% |
| 3 Month Change | -51.29% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.27% |
Recent News & Updates
Shareholder Returns
| KYTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.1% | -4.9% | -5.7% |
| 1Y | n/a | 11.5% | 14.1% |
Return vs Industry: Insufficient data to determine how KYTX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how KYTX performed against the US Market.
Price Volatility
| KYTX volatility | |
|---|---|
| KYTX Average Weekly Movement | 16.7% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KYTX's share price has been volatile over the past 3 months.
Volatility Over Time: KYTX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 100 | Peter Maag | kyvernatx.com |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases.
Kyverna Therapeutics, Inc. Fundamentals Summary
| KYTX fundamental statistics | |
|---|---|
| Market cap | US$300.94m |
| Earnings (TTM) | -US$75.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.9x
P/E RatioIs KYTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$63.69m |
| Gross Profit | -US$63.69m |
| Other Expenses | US$12.23m |
| Earnings | -US$75.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KYTX perform over the long term?
See historical performance and comparison